Repligen Announces Licensing Agreement With Pfizer for Spinal Muscular

Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular

Filed under: residential drug treatment programs

The SMA program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Under the terms of the agreement, Repligen is entitled to receive up to $ 70 million from Pfizer, …
Read more on DailyFinance

 

Recommendations made to improve access to substance abuse treatment

Filed under: residential drug treatment programs

In their report, members of the Program Review and Investigations Committee say lawmakers should require those deciding on insurance coverage to have expertise or a background in treating substance abuse. Current law is less stringent, requiring …
Read more on The Connecticut Mirror

 

Port St. Lucie transitional housing issue could take center stage in legislature

Filed under: residential drug treatment programs

City Council has agreed to lobby state legislators in March to help amend or reform a federal law that allows drug and alcohol rehab treatment centers to build transition homes for recovering addicts in single-family residential neighborhoods. The …
Read more on Fort Pierce Tribune

 

2 Biotech Companies Making Considerable Strides When It Comes To Pain

Filed under: residential drug treatment programs

Zalicus (ZLCS): According to its website, "Zalicus is a biopharmaceutical company which engages in the discovery and development of drug candidates focusing on the treatment of pain and inflammation". Zalicus is primarily focused on the development of …
Read more on Seeking Alpha